PharmaCorp Rx Balance Sheet Health
Financial Health criteria checks 5/6
PharmaCorp Rx has a total shareholder equity of CA$30.1M and total debt of CA$412.5K, which brings its debt-to-equity ratio to 1.4%. Its total assets and total liabilities are CA$32.1M and CA$2.0M respectively.
Key information
1.4%
Debt to equity ratio
CA$412.47k
Debt
| Interest coverage ratio | n/a |
| Cash | CA$26.68m |
| Equity | CA$30.07m |
| Total liabilities | CA$2.01m |
| Total assets | CA$32.08m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PCRX's short term assets (CA$27.3M) exceed its short term liabilities (CA$640.5K).
Long Term Liabilities: PCRX's short term assets (CA$27.3M) exceed its long term liabilities (CA$1.4M).
Debt to Equity History and Analysis
Debt Level: PCRX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if PCRX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PCRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: PCRX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 105.8% each year